The combination of advanced gene delivery methods, such as transfection, with immunotherapy research has opened exciting new horizons for treating blood cancers. Immunotherapy harnesses the patient’s immune system to target and eliminate malignant cells, often through engineered immune cells or immune checkpoint modulation. Transfection techniques allow scientists to genetically modify immune cells, such as T…
Xenograft models play a pivotal role in the preclinical development pipeline for blood cancer therapies, serving as an essential bridge between in vitro research and human clinical trials. The U.S. Food and Drug Administration (FDA) requires robust preclinical data to assess the safety, efficacy, and pharmacokinetics of new drugs before approving their progression into clinical…
Achieving efficient gene delivery into hematologic cancer cells requires careful optimization due to their suspension culture, delicate membranes, and sensitivity to physical stress. Unlike adherent cells that attach to culture vessels, blood cancer cells grow floating in medium, reducing their interaction time with transfection reagents and complicating uptake. Electroporation remains the most effective technique for…
CD19 and CD20 are integral surface markers expressed on most B cells and represent prime therapeutic targets in B-cell lymphomas and leukemias. Their restricted expression on B cells allows for selective targeting, minimizing damage to other tissues. CD20 is a transmembrane protein involved in B-cell activation and proliferation. Therapeutic antibodies targeting CD20, such as rituximab,…
In vivo xenograft models, where human leukemia cells are implanted into immunocompromised mice, have become indispensable tools in preclinical oncology research. These models offer a physiologically relevant environment to study tumor biology, drug efficacy, and resistance mechanisms in ways that in vitro cultures cannot replicate. Leukemia xenografts can be established using either subcutaneous implantation, which…
Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML) are both malignancies arising from myeloid lineage cells but differ significantly in pathogenesis, progression, and treatment response. AML is characterized by the rapid accumulation of immature myeloid blasts, leading to bone marrow failure. CML involves the gradual expansion of mature granulocytes driven by the BCR-ABL fusion…
CRISPR-Cas9 technology has revolutionized gene editing by providing precise, efficient tools to modify the genome. However, applying CRISPR to suspension cells such as leukemia and lymphoma lines remains technically challenging. These cells’ non-adherent nature and sensitivity to physical and chemical manipulation require specialized protocols to achieve effective gene editing without compromising cell viability. The most…
Small interfering RNA (siRNA) technology enables targeted gene silencing by harnessing the cell’s natural RNA interference pathway. This approach allows researchers to transiently reduce or eliminate the expression of genes of interest, providing powerful insights into gene function and disease mechanisms. In leukemia research, siRNA knockdown helps dissect the roles of oncogenes, tumor suppressors, signaling…
Gene delivery into leukemia cells is critical for functional genomics, drug target validation, and therapeutic development. Among the many transfection techniques, electroporation and lipofection are the two most commonly employed methods, each with distinct advantages and limitations. Lipofection uses cationic lipid molecules to form complexes with negatively charged nucleic acids, facilitating their uptake into cells…
Transfecting blood-derived cells—particularly leukemia and lymphoma cell lines—poses a unique set of challenges for researchers. Unlike adherent cells such as fibroblasts or epithelial lines, blood cells grow in suspension, lack strong cell–cell contact, and have distinct membrane properties that make them resistant to conventional transfection techniques like lipofection or calcium phosphate precipitation. Their high proliferation…
